Skip to main content
Erschienen in: Annals of Surgical Oncology 4/2019

08.02.2019 | Thoracic Oncology

Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy

verfasst von: Takafumi Soeno, MD, Hiroki Harada, MD, Kei Hosoda, MD, PhD, FACS, Hiroaki Mieno, MD, PhD, Akira Ema, MD, PhD, Hideki Ushiku, MD, PhD, Marie Washio, MD, Yoshimasa Kosaka, MD, PhD, Masahiko Watanabe, MD, PhD, FACS, Keishi Yamashita, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study is to elucidate the optimized lymph node dissection range in middle thoracic (Mt) esophageal squamous cell carcinoma (ESCC) requiring surgery.

Patients and Methods

We retrospectively analyzed 165 ESCC patients who underwent surgery with curative intent between 2009 and 2016, including 99 (60%) with MtESCC. Preoperative chemotherapy was administered in more than 80% of cStage II/III MtESCC patients. The rates of pathological and potential metastasis (representing recurrences) to lymph nodes and prognosis (median follow-up 52 months) were clarified. Lymph node dissection efficacy was assessed by calculating the efficacy index (EI) for each lymph node.

Results

No. 2R had the highest rate of metastasis, with frequencies of 13/38/46% in cStage I/II/III, respectively, with the highest EI in MtESCC. Recurrences were seen in about 2–10% in the regional (nos. 1, 2L, 4R, and 10) and extraregional lymph nodes (paraaortic lymph node). The EI of lymph nodes was found to exhibit the highest score of 15 for no. 2R, followed by 11.5 for no. 17. The 5-year overall survival (OS) in MtESCC patients who underwent no. 2R lymph node dissection was 73.8%, while those who did not undergo no. 2R dissection did never reach 5-year OS (P = 0.002).

Conclusions

Meticulous lymph node dissection of no. 2R is the most important for long-term survival, and mandatory with the highest priority in MtESCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–86, 2015CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–86, 2015CrossRefPubMed
2.
Zurück zum Zitat Wu SG, Dai MM, He ZY, et al. Patterns of regional lymph node recurrence after radical surgery for thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 101:551–7, 2016CrossRefPubMed Wu SG, Dai MM, He ZY, et al. Patterns of regional lymph node recurrence after radical surgery for thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 101:551–7, 2016CrossRefPubMed
4.
Zurück zum Zitat Kumakura Y, Yokobori T, Yoshida T, et al. Elucidation of the anatomical mechanism of nodal skip metastasis in superficial thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 25:1221–1228, 2018CrossRefPubMedPubMedCentral Kumakura Y, Yokobori T, Yoshida T, et al. Elucidation of the anatomical mechanism of nodal skip metastasis in superficial thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 25:1221–1228, 2018CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Liu J, Liu Q, Wang Y, et al. Nodal skip metastasis is associated with a relatively poor prognosis in thoracic esophageal squamous cell carcinoma. Eur J Surg Oncol. 42:1202–5, 2016CrossRefPubMed Liu J, Liu Q, Wang Y, et al. Nodal skip metastasis is associated with a relatively poor prognosis in thoracic esophageal squamous cell carcinoma. Eur J Surg Oncol. 42:1202–5, 2016CrossRefPubMed
6.
Zurück zum Zitat Wang F, Zheng Y, Wang Z, et al. Nodal skip metastasis in esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Thorac Surg. 104:1187–1193, 2017CrossRefPubMed Wang F, Zheng Y, Wang Z, et al. Nodal skip metastasis in esophageal squamous cell carcinoma patients undergoing three-field lymphadenectomy. Ann Thorac Surg. 104:1187–1193, 2017CrossRefPubMed
7.
Zurück zum Zitat Feng JF, Zhao Q, Chen QX. Prognostic value of subcarinal lymph node metastasis in patients with esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 14:3183–6, 2013CrossRefPubMed Feng JF, Zhao Q, Chen QX. Prognostic value of subcarinal lymph node metastasis in patients with esophageal squamous cell carcinoma. Asian Pac J Cancer Prev. 14:3183–6, 2013CrossRefPubMed
8.
Zurück zum Zitat Niwa Y, Koike M, Hattori M, et al. The prognostic relevance of subcarinal lymph node dissection in esophageal squamous cell carcinoma. Ann Surg Oncol. 23:611–8, 2016CrossRefPubMed Niwa Y, Koike M, Hattori M, et al. The prognostic relevance of subcarinal lymph node dissection in esophageal squamous cell carcinoma. Ann Surg Oncol. 23:611–8, 2016CrossRefPubMed
9.
Zurück zum Zitat Miyata H, Yamasaki M, Makino T, et al. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. J Surg Oncol. 112:60–5, 2015CrossRefPubMed Miyata H, Yamasaki M, Makino T, et al. Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. J Surg Oncol. 112:60–5, 2015CrossRefPubMed
10.
Zurück zum Zitat Wang ZQ, Deng HY, Hu Y, et al. Prognostic value of right upper mediastinal lymphadenectomy in Sweet procedure for esophageal cancer. J Thorac Dis. 8:3625–3632, 2016CrossRefPubMedPubMedCentral Wang ZQ, Deng HY, Hu Y, et al. Prognostic value of right upper mediastinal lymphadenectomy in Sweet procedure for esophageal cancer. J Thorac Dis. 8:3625–3632, 2016CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Hsu PK, Huang CS, Hsieh CC, et al. Role of right upper mediastinal lymph node metastasis in patients with esophageal squamous cell carcinoma after tri-incisional esophagectomies. Surgery. 156:1269–77, 2014CrossRefPubMed Hsu PK, Huang CS, Hsieh CC, et al. Role of right upper mediastinal lymph node metastasis in patients with esophageal squamous cell carcinoma after tri-incisional esophagectomies. Surgery. 156:1269–77, 2014CrossRefPubMed
12.
Zurück zum Zitat Yamashita K, Makino T, Yamasaki M, et al. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer. Dis Esophagus. 30:1–8, 2017CrossRef Yamashita K, Makino T, Yamasaki M, et al. Comparison of short-term outcomes between 2- and 3-field lymph node dissection for esophageal cancer. Dis Esophagus. 30:1–8, 2017CrossRef
13.
Zurück zum Zitat Yamashita K, Katada N, Moriya H, et al. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Gen Thorac Cardiovasc Surg. 64:209–15, 2016CrossRefPubMed Yamashita K, Katada N, Moriya H, et al. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis. Gen Thorac Cardiovasc Surg. 64:209–15, 2016CrossRefPubMed
14.
Zurück zum Zitat Yamashita K, Hosoda K, Moriya H, et al. Prognostic advantage of docetaxel/cisplatin/5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 92:221–228, 2017CrossRefPubMed Yamashita K, Hosoda K, Moriya H, et al. Prognostic advantage of docetaxel/cisplatin/5-fluorouracil neoadjuvant chemotherapy in clinical stage II/III esophageal squamous cell carcinoma due to excellent control of preoperative disease and postoperative lymph node recurrence. Oncology. 92:221–228, 2017CrossRefPubMed
15.
Zurück zum Zitat Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74, 2012CrossRefPubMed Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 19:68–74, 2012CrossRefPubMed
16.
Zurück zum Zitat Harada H, Hosoda K, Moriya H, et al. Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis. Oncol Lett. 16:3281–89, 2018PubMedPubMedCentral Harada H, Hosoda K, Moriya H, et al. Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis. Oncol Lett. 16:3281–89, 2018PubMedPubMedCentral
17.
Zurück zum Zitat Hosoda K, Yamashita K, Katada N, et al. Impact of lower mediastinal lymphadenectomy for the treatment of esophagogastric junction carcinoma. Anticancer Res. 35:445–56, 2015PubMed Hosoda K, Yamashita K, Katada N, et al. Impact of lower mediastinal lymphadenectomy for the treatment of esophagogastric junction carcinoma. Anticancer Res. 35:445–56, 2015PubMed
18.
Zurück zum Zitat Park SY, Kim DJ, Jung HS, et al. Relationship between the size of metastatic lymph nodes and positron emission tomographic/computer tomographic findings in patients with esophageal squamous cell carcinoma. World J Surg. 39:2948–54, 2015CrossRefPubMed Park SY, Kim DJ, Jung HS, et al. Relationship between the size of metastatic lymph nodes and positron emission tomographic/computer tomographic findings in patients with esophageal squamous cell carcinoma. World J Surg. 39:2948–54, 2015CrossRefPubMed
19.
Zurück zum Zitat Yu S, Lin J, Chen C, et al. Recurrent laryngeal nerve lymph node dissection may not be suitable for all early stage esophageal squamous cell carcinoma patients: an 8-year experience. J Thorac Dis. 8:2803–12, 2016CrossRefPubMedPubMedCentral Yu S, Lin J, Chen C, et al. Recurrent laryngeal nerve lymph node dissection may not be suitable for all early stage esophageal squamous cell carcinoma patients: an 8-year experience. J Thorac Dis. 8:2803–12, 2016CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Mine S, Watanabe M, Imamura Y, et al. Clinical significance of the pre-therapeutic nodal size in patients undergoing neo-adjuvant treatment followed by esophagectomy for esophageal squamous cell carcinoma. World J Surg. 41:184–90, 2017CrossRefPubMed Mine S, Watanabe M, Imamura Y, et al. Clinical significance of the pre-therapeutic nodal size in patients undergoing neo-adjuvant treatment followed by esophagectomy for esophageal squamous cell carcinoma. World J Surg. 41:184–90, 2017CrossRefPubMed
21.
Zurück zum Zitat Makino T, Yamasaki M, Miyata H, et al. Solitary lymph node recurrence of esophageal squamous cell carcinoma: surgical failure or systemic disease? Ann Surg Oncol. 23:2087–93, 2016CrossRefPubMed Makino T, Yamasaki M, Miyata H, et al. Solitary lymph node recurrence of esophageal squamous cell carcinoma: surgical failure or systemic disease? Ann Surg Oncol. 23:2087–93, 2016CrossRefPubMed
Metadaten
Titel
Lymph Node Progression and Optimized Node Dissection of Middle Thoracic Esophageal Squamous Cell Carcinoma in the Latest Therapeutic Surgical Strategy
verfasst von
Takafumi Soeno, MD
Hiroki Harada, MD
Kei Hosoda, MD, PhD, FACS
Hiroaki Mieno, MD, PhD
Akira Ema, MD, PhD
Hideki Ushiku, MD, PhD
Marie Washio, MD
Yoshimasa Kosaka, MD, PhD
Masahiko Watanabe, MD, PhD, FACS
Keishi Yamashita, MD, PhD, FACS
Publikationsdatum
08.02.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07190-5

Weitere Artikel der Ausgabe 4/2019

Annals of Surgical Oncology 4/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.